The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week.
iPump, developed in conjunction with Stallergenes Greer, supports adherence to personalized SLIT treatments. It helps to ensure patients adopt the correct dosing technique, duration and frequency of treatment. The easy-to-use tool connects to a companion mobile application and provides direct access to personalized treatment protocols.
Launched in February 2023 in France, more than 9,000 patients ahve used iPump to date to improve treatment adherence.
Aptar said the SPEED survey demonstrated a 15% increase in treatment adherence for patients using iPump. In children aged between five and 12 years, parental involvement in treatment administration dropped from 50% to 28% over three months. Meanwhile, the proportion of children independently taking medication rose from 24% to 58%.
Notably, 90% of parents felt reassured by the connected assistant. Half felt completely at ease with treatment administration, compared to 36% in the non-iPump group.
Aptar says the survey results establish a strong foundation for broader adoption of iPump.
Aptar Digital Health VP of Business Development & Global Head of Respiratory, Marcus Bates, said: “The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes.”
